摘要
肾素-血管紧张素-醛固酮系统在心力衰竭发生发展过程中起着关键作用。尽管既往治疗心力衰竭的药物已经取得了很好的疗效,但心力衰竭患者的死亡率和因心衰再入院率仍比较高。沙库巴曲缬沙坦是一种双重阻断神经内分泌的抑制剂,研究证明,沙库巴曲缬沙坦较血管紧张素转化酶抑制剂类药物能进一步降低心血管死亡风险,从而改善心衰的治疗效果。本文主要就沙库巴曲缬沙坦在三种不同类型心衰中有效性和安全性进行综述,旨在为临床治疗心力衰竭提供参考依据。
The renin-angiotensin-aldosterone system plays a key role in the development of heart failure.Although the previous drugs for the treatment of heart failure have achieved good results,the mortality and readmission rates of heart failure patients are still relatively high.Sacubitrilvalsartan is a dual-blocking neuroendocrine inhibitor.Studies have shown that sacubitril valsartan can further reduce the risk of cardiovascular death compared with angiotensin-converting enzyme inhibitor drugs,thereby improving the heart therapeutic effect of aging.This article mainly reviews the effectiveness and safety of sacubitril valsartan in three different types of heart failure,aiming to provide a reference for the clinical treatment of heart failure.
作者
王晨青
李婧炜
WANG Chen-qing;LI Jing-wei(School of Pharmacy,Dali University,Dali 671000,Yunnan,China)
出处
《医学信息》
2021年第1期37-40,共4页
Journal of Medical Information
基金
云南省中青年学术带头人后备人才计划(编号:2019HB054)
云南省应用基础研究计划面上项目(编号:2017FB140)。
